neuroelectrics

Brain stimulation tech developer Neuroelectrics announced today that it’s secured FDA breakthrough device designation for its Starstim neuromodulation platform to treat refractory focal epilepsy.

Starstim includes transcranial electrical stimulation (tES), personalized treatment protocols and a secure cloud-based mechanism to deliver treatment anywhere.

“We are excited to receive the FDA Breakthrough Device Designation for our lead program in refractory focal epilepsy. We hope that it will speed the evaluation of a new therapeutic modality that could potentially help patients who currently have no effective treatments available,” said Neuroelectrics co-founder and CEO Ana Maiques said in a news release.

The Cambridge, Mass./Barcelona, Spain–based  company recently completed a pilot study of its Starstim tES system in 20 adult and pediatric patients with medically refractory focal epilepsy. The study found a 44% median reduction in seizure frequency…

Brain stimulation technology developer Neuroelectrics announced today that it raised $17.5 million in a Series A financing.

Morningside Ventures led the funding round, the proceeds for which are earmarked for the development of Neuroelectrics’ non-invasive transcranial electrical stimulation (tES) therapeutic platform.

Cambridge, Mass./Barcelona, Spain-based Neuroelectrics plans to use funds to advance clinical trials for the platform in treating refractory focal epilepsy and the at-home treatment of refractory depression, according to a news release.

“Neuroelectrics is developing a platform that builds upon the brain’s natural electrical properties to both understand and treat neurological dysfunction. Our goal is to offer a safe, non-invasive option that benefits those for whom effective treatments are unavailable,” Neuroelectrics co-founder Ana Maiques said in the release. “Our investors share this vision, and we are gr…